laromestrocel

all catalysts(0)

nothing on the calendar yet

News(3)

• Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
  Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
  biopharma_dive · 12d ago
• Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
  With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a strategic review after the failure of a cardiovascular study.
  biospace · 13d ago
• Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
  A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.
  fiercebiotech · 13d ago